Quest Diagnostics (DGX) to Release Earnings on Tuesday

Key Points

• Quest Diagnostics is scheduled to release its Q3 2025 earnings on October 21st, with analysts projecting earnings of $2.51 per share and revenue of $2.734 billion.
• The company recently reported a net margin of 9.01% and a year-over-year revenue increase of 15.2% in its last quarterly earnings.
• Quest Diagnostics also declared a quarterly dividend of $0.80, which will be paid on October 20th, reflecting an annualized yield of 1.8%.

Quest Diagnostics (NYSE:DGX - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Tuesday, October 21st. Analysts expect Quest Diagnostics to post earnings of $2.51 per share and revenue of $2.7340 billion for the quarter. Quest Diagnostics has set its FY 2025 guidance at 9.630-9.830 EPS.Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, October 21, 2025 at 8:30 AM ET.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.62 earnings per share for the quarter, topping analysts' consensus estimates of $2.57 by $0.05. The business had revenue of $2.76 billion during the quarter, compared to analysts' expectations of $2.73 billion. Quest Diagnostics had a net margin of 9.01% and a return on equity of 15.24%. Quest Diagnostics's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.35 earnings per share. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Stock Performance

Shares of DGX opened at $182.81 on Tuesday. The company has a market capitalization of $20.44 billion, a PE ratio of 21.89, a price-to-earnings-growth ratio of 2.44 and a beta of 0.56. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 0.99. Quest Diagnostics has a one year low of $146.91 and a one year high of $191.49. The company's fifty day moving average price is $181.42 and its 200 day moving average price is $175.72.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 20th. Stockholders of record on Friday, October 3rd will be paid a $0.80 dividend. The ex-dividend date is Friday, October 3rd. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.8%. Quest Diagnostics's payout ratio is presently 38.32%.

Analysts Set New Price Targets

Several brokerages have commented on DGX. Wall Street Zen downgraded Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Truist Financial boosted their target price on shares of Quest Diagnostics from $190.00 to $192.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. William Blair reissued an "outperform" rating on shares of Quest Diagnostics in a report on Wednesday, July 23rd. Baird R W lowered shares of Quest Diagnostics from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 25th. Finally, Robert W. Baird reaffirmed a "neutral" rating and set a $194.00 price objective on shares of Quest Diagnostics in a research report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of "Moderate Buy" and a consensus price target of $186.63.

Insider Activity

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 2,210 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, July 31st. The stock was sold at an average price of $170.00, for a total transaction of $375,700.00. Following the sale, the senior vice president directly owned 8,450 shares of the company's stock, valued at approximately $1,436,500. The trade was a 20.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Patrick Plewman sold 1,975 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $185.00, for a total value of $365,375.00. Following the completion of the sale, the senior vice president owned 15,269 shares in the company, valued at approximately $2,824,765. This represents a 11.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,186 shares of company stock worth $9,647,471. Corporate insiders own 8.16% of the company's stock.

Institutional Trading of Quest Diagnostics

A number of large investors have recently bought and sold shares of DGX. Brighton Jones LLC bought a new position in shares of Quest Diagnostics during the fourth quarter valued at $323,000. Advisory Services Network LLC acquired a new stake in shares of Quest Diagnostics during the 2nd quarter worth about $591,000. Tidal Investments LLC lifted its holdings in Quest Diagnostics by 26.1% during the 2nd quarter. Tidal Investments LLC now owns 3,098 shares of the medical research company's stock valued at $556,000 after purchasing an additional 641 shares during the last quarter. Diversify Advisory Services LLC boosted its position in Quest Diagnostics by 123.6% in the second quarter. Diversify Advisory Services LLC now owns 3,101 shares of the medical research company's stock valued at $554,000 after buying an additional 1,714 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new stake in Quest Diagnostics during the second quarter worth about $327,000. 88.06% of the stock is currently owned by institutional investors.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.